An article from
News roundup
Voyxact helped preserve kidney function, but left an opening for competing IgAN drugs from Vera and Vertex. Elsewhere, Takeda’s alliance with Innovent paid early dividends.
Published June 4, 2026
Getty Images
Otsuka showcases kidney drug data; Pfizer cuts an AI deal
Voyxact helped preserve kidney function, but left an opening for competing IgAN drugs from Vera and Vertex. Elsewhere, Takeda’s alliance with Innovent paid early dividends and Axsome warded off generic competitors.
497 words~2 min read
